Companies › Beijing Pearl Biotechnology Limited Liability Company
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PLB1001 (Vebreltinib) MET inhibitor | MET | Phase 3 | Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Glioblastoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06105619 | PLB1001 (Vebreltinib) | Phase 2 | Glioblastoma | Oncology | Dec 2026 |
| NCT05989542 | PLB1001 (Vebreltinib) | Phase 3 | Non-small Cell Lung Cancer | Oncology | Sep 2027 |
| NCT06930794 | PLB1001 (Vebreltinib) | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Feb 2029 |
Apollomics Abion LaNova Medicines Zhejiang Quetzal Therapeutics Quercis Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.